AMCP Annual 2024
April 15-18, 2024
View More
Perspectives on Emerging Data for the Use of Immunotherapy in the Treatment of Early-Stage Non-Small Cell Lung Cancer
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Reducing the Clinical and Economic Burden of Managing IgA Nephropathy With Emerging Therapies: A Review for Specialty Pharmacists
1.5 Credits / Nephrology
View More
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Standard Criteria for Loss of Ambulation Needed in DMD
A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.